Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States

Figures

• 

  Figure 1. Parechovirus A3 (PeV-A3 neutralizing antibody (nAb) seropositivity, Australia, the Netherlands, and United States. A) Overall nAb seropositivity with associated 95% CIs. Infants <1 year of age were excluded from the analysis. Seropositivity rates between the timepoints within each location were compared by using χ2 tests. B) Overall age-stratified PeV-A3 nAb seropositivity, including infants <1 year of age. Seropositivity was determined as a nAb titer of ≥1:8 or ≥1:32. C–F) Age-stratified PeV-A3 nAb seropositivity in C) the Netherlands; D) Missouri, USA; E) Victoria, Australia; and F) New South Wales, Australia. Complete data used in this figure can be found in the Appendix (http://wwwnc.cdc.gov/EID/article/25/1/18-0352-App1.pdf). AUS, Australia; NL, the Netherlands; NSW, New South Wales; VIC, Victoria.

• 

  Figure 2. Age-associated GMTs of parechovirus A3 neutralizing antibodies, Australia, the Netherlands, and United States. Bars indicate overall GMTs (timepoints and locations merged); error bars indicate SDs. Lines represent GMTs in each location (timepoints merged). AUS, Australia; GMT, geometric mean titer; NL, Netherlands; VIC, Victoria; NSW, New South Wales.